Literature DB >> 12775976

Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice.

Shlomo Keidar1, Tony Hayek, Marielle Kaplan, Elsa Pavlotzky, Shadi Hamoud, Raymond Coleman, Michael Aviram.   

Abstract

Oxidative stress is involved in the pathogenesis of atherosclerosis, and angiotensin II (AT-II) induces oxidative stress and enhances atherogenesis. Aldosterone, which has an important role in the pathology of heart failure, has recently been implicated as a mediator of AT-II biologic activities. In this study, we analyzed whether administration of the selective aldosterone blocker eplerenone to atherosclerotic apolipoprotein E-deficient (E0) mice would affect their oxidative status and atherogenesis. Apolipoprotein E-deficient mice were administered chow containing eplerenone (200 mg/kg/day) for 3 months. Blood pressure, serum and macrophage oxidative status, and aortic atherosclerotic lesion area were evaluated in mice treated with eplerenone compared with untreated mice. Eplerenone administration significantly decreased systolic and diastolic blood pressure by 12% and 11%, respectively, compared with untreated mice. Serum susceptibility to lipid peroxidation decreased by as much as 26%, and serum paraoxonase activity increased by 28% in eplerenone-treated mice compared with untreated mice. Peritoneal macrophages from eplerenone-treated mice contained reduced levels of lipid peroxides, and their macrophage oxidation of low-density lipoprotein (LDL) and superoxide ion release were significantly reduced (by 17% and 43%, respectively), compared to untreated mice. Daily injections of AT-II (0.1 mL, 10(-)7M) during the final 3 weeks of the study in eplerenone-treated mice substantially attenuated the eplerenone-mediated reduction in macrophage superoxide release and LDL oxidation. Finally, the atherosclerotic lesion area in aortas of eplerenone-treated mice was significantly reduced (by 35%) versus untreated mice, and this effect was reversed by AT-II. Administration of the selective aldosterone blocker eplerenone significantly reduced oxidative stress and atherosclerosis progression in E0 mice. These data suggest that aldosterone could have a significant pro-oxidative role in the pathogenesis of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12775976     DOI: 10.1097/00005344-200306000-00019

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  38 in total

Review 1.  Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications.

Authors:  Mindy Markowitz; Frank Messineo; Neil L Coplan
Journal:  Clin Cardiol       Date:  2012-07-06       Impact factor: 2.882

2.  Essential role of ICAM-1 in aldosterone-induced atherosclerosis.

Authors:  Vincenzo Marzolla; Andrea Armani; Caterina Mammi; Mary E Moss; Vittoria Pagliarini; Laura Pontecorvo; Antonella Antelmi; Andrea Fabbri; Giuseppe Rosano; Iris Z Jaffe; Massimiliano Caprio
Journal:  Int J Cardiol       Date:  2017-01-05       Impact factor: 4.164

3.  Aldosterone and thrombosis formation: implications for ischemic and atherosclerotic heart disease.

Authors:  L A Calò; D Armanini
Journal:  J Endocrinol Invest       Date:  2006 Jul-Aug       Impact factor: 4.256

4.  Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.

Authors:  Kristen L Nowak; Berenice Gitomer; Heather Farmer-Bailey; Wei Wang; Mikaela Malaczewski; Jelena Klawitter; Zhiying You; Diana George; Nayana Patel; Anna Jovanovich; Michel Chonchol
Journal:  Am J Kidney Dis       Date:  2019-02-23       Impact factor: 8.860

5.  Renal denervation attenuates progression of atherosclerosis in apolipoprotein E-deficient mice independent of blood pressure lowering.

Authors:  Hui Wang; Jintao Wang; Chiao Guo; Wei Luo; Kyle Kleiman; Daniel T Eitzman
Journal:  Hypertension       Date:  2015-02-02       Impact factor: 10.190

Review 6.  Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease.

Authors:  Nicholas C Bene; Pilar Alcaide; Henry H Wortis; Iris Z Jaffe
Journal:  Steroids       Date:  2014-04-21       Impact factor: 2.668

Review 7.  Mineralocorticoid receptors in vascular function and disease.

Authors:  Amy McCurley; Iris Z Jaffe
Journal:  Mol Cell Endocrinol       Date:  2011-06-24       Impact factor: 4.102

8.  Mineralocorticoid Receptor Deficiency in Macrophages Inhibits Atherosclerosis by Affecting Foam Cell Formation and Efferocytosis.

Authors:  Zhu-Xia Shen; Xiao-Qing Chen; Xue-Nan Sun; Jian-Yong Sun; Wu-Chang Zhang; Xiao-Jun Zheng; Yu-Yao Zhang; Huan-Jing Shi; Jia-Wei Zhang; Chao Li; Jun Wang; Xu Liu; Sheng-Zhong Duan
Journal:  J Biol Chem       Date:  2016-11-23       Impact factor: 5.157

Review 9.  Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.

Authors:  Adam P McGraw; Amy McCurley; Ioana R Preston; Iris Z Jaffe
Journal:  Curr Atheroscler Rep       Date:  2013-07       Impact factor: 5.113

10.  Oxidative stress-related proteins in a Conn's adenoma tissue. Relevance for aldosterone's prooxidative and proinflammatory activity.

Authors:  L A Calò; E Pagnin; P A Davis; D Armanini; P Mormino; G P Rossi; A C Pessina
Journal:  J Endocrinol Invest       Date:  2009-07-21       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.